Perneczky, R
The appropriateness of short cognitive tests for the identification of mild cognitive impairment and mild dementia
Aktuelle Neurologie
2003
30
3
114-117

Behnke, K;Søgaard, J;Martin, S;Bäuml, J;Ravindran, AV;Agren, H;Vester-Blokland, ED
Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
J Clin Psychopharmacol
2003
23
4
358-64

Wiedemann, G;Klingberg, S;Pitschel-Walz, G
Psychoeducational interventions in the treatment of patients with schizophrenic disorders
Nervenarzt
2003
74
9
789-806

Förstl, H
Memantine - A viewpoint
Drugs Aging
2003
20
6
477-477

Kurz, A;Erkinjuntti, T;Bullock, R;Lilienfeld, S;Brashear, HR
Long-term safety, tolerability, and efficacy of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease: An interim analysis
Int Psychogeriatr
2003
15 Suppl.
273-273

Pasquier, F;Fukui, T;Sarazin, M;Pijnenburg, Y;Diehl, J;Grundman, M;Miller, BL
Laboratory investigations and treatment in frontotemporal dementia
Ann Neurol
2003
54 Suppl.
S32-S35

Depboylu, C;Du, YS;Müller, U;Kurz, A;Zimmer, R;Riemenschneider, M;Gasser, T;Oertel, WH;Klockgether, T;Dodel, RC
Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease (vol 342, pg 132, 2003)
Neurosci Lett
2003
349
3
212-212

Riemenschneider, M
The diagnosis of Alzheimer disease before it is Alzheimer dementia - In reply
Arch Neurol
2003
60
7
1023-1024

Scherer, J;Albus, M;Förstl, H;Jahn, T;Mager, T;Tatsch, K
D-2 dopamine receptor occupancy during treatment with flupentixol decanoate in comparison to risperidone, olanizapine, clozapine, haloperidol and haloperidol decanoate - A I-123-IBZM SPECT study: D-2 receptor occupancy under flupentixol decanoate
Pharmacopsychiatry
2003
36
5
259-260

Seemann, U;Schwarz, C;Janssen, B;Kissling, W
Subjective quality of life and treatment strategies in schizophrenia outpatient care
Pharmacopsychiatry
2003
36
5
265-265